Completed OBSERVATIONAL NCT00232193

Safety/Effectiveness of Adding Monthly Dexamethasone to Weekly Avonex for MS

Steroid Adjunctive Treatment at Initiation of Avonex Therapy for Patients With Mono-Symptomatic or Relapsing-Remitting Multiple Sclerosis

Sponsor: Biogen

Conditions Clinically Isolated Syndrome Relapsing-remitting Multiple Sclerosis

Updated 6 times since 2017 Last updated: Jul 20, 2011 Started: Dec 31, 2003 Primary completion: Dec 31, 2008 Completion: Aug 31, 2010

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00232193, this observational or N/A phase trial focuses on Clinically Isolated Syndrome and Relapsing-remitting Multiple Sclerosis and remains completed. Sponsored by Biogen, it has been updated 6 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed
Jul 2024 — Sep 2024 [monthly]

Completed
Jan 2021 — Jul 2024 [monthly]

Completed
Jun 2018 — Jan 2021 [monthly]

Completed
Apr 2018 — Jun 2018 [monthly]

Completed

Phase: PHASE4 → None

▶ Show 1 earlier version

Jan 2017 — Apr 2018 [monthly]

Completed PHASE4

First recorded

Dec 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Biogen
Providence Multiple Sclerosis Center

Data source: Providence Multiple Sclerosis Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Portland, United States